BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 306] [Cited by in F6Publishing: 289] [Article Influence: 102.0] [Reference Citation Analysis]
Number Citing Articles
1 Li L, Ma C, Hurilebagen, Yuan H, Hu R, Wang W, Weilisi. Effects of lactoferrin on intestinal flora of metabolic disorder mice. BMC Microbiol 2022;22. [DOI: 10.1186/s12866-022-02588-w] [Reference Citation Analysis]
2 Wupperfeld D, Fricker G, Bois De Fer B, Frank L, Wehrle A, Popovic B. Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell lines. Lipids Health Dis 2022;21. [DOI: 10.1186/s12944-022-01698-8] [Reference Citation Analysis]
3 Wang X, Han Y, Liu Y, Hu H. Association between serum uric acid-to-creatinine ratio and non-alcoholic fatty liver disease: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02500-w] [Reference Citation Analysis]
4 Leone A, Bertoli S, Bedogni G, Vignati L, Pellizzari M, Battezzati A. Association between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity. Nutrients 2022;14:3771. [DOI: 10.3390/nu14183771] [Reference Citation Analysis]
5 Yang K, Chen J, Zhang T, Yuan X, Ge A, Wang S, Xu H, Zeng L, Ge J. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front Immunol 2022;13:949746. [DOI: 10.3389/fimmu.2022.949746] [Reference Citation Analysis]
6 Tsankof A, Neokosmidis G, Koureta E, Veneti S, Cholongitas E, Tziomalos K. Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease? Front Endocrinol 2022;13:984041. [DOI: 10.3389/fendo.2022.984041] [Reference Citation Analysis]
7 Xie Y, Kong W, Wang X, Wu Z. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01134-z] [Reference Citation Analysis]
8 Jia M, Xiao Y, Zhang C, Jiang T, Huang Y, Gao J, Li Y, Zhou L. Mitoxantrone alleviates hepatic steatosis induced by high-fat diet in broilers. Biochem Biophys Res Commun 2022;627:52-9. [PMID: 36007336 DOI: 10.1016/j.bbrc.2022.08.042] [Reference Citation Analysis]
9 Kim J, Yang Y, Kwon E, Choi J. Novel Plant Extract Ameliorates Metabolic Disorder through Activation of Brown Adipose Tissue in High-Fat Diet-Induced Obese Mice. IJMS 2022;23:9295. [DOI: 10.3390/ijms23169295] [Reference Citation Analysis]
10 Li D, Zhang M, Wu S, Tan H, Li N. Risk factors and prediction model for nonalcoholic fatty liver disease in northwest China. Sci Rep 2022;12:13877. [PMID: 35974018 DOI: 10.1038/s41598-022-17511-6] [Reference Citation Analysis]
11 Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, Kassi E, Papavassiliou AG. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells 2022;11:2511. [PMID: 36010588 DOI: 10.3390/cells11162511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Meng LC, Zheng JY, Qiu YH, Zheng L, Zheng JY, Liu YQ, Miao XL, Lu XY. Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice. Int Immunopharmacol 2022;111:109099. [PMID: 35932615 DOI: 10.1016/j.intimp.2022.109099] [Reference Citation Analysis]
13 Zeng S, Chen Y, Wei C, Tan L, Li C, Zhang Y, Xu F, Zhu K, Wu G, Cao J. Protective effects of polysaccharide from Artocarpus heterophyllus Lam. (jackfruit) pulp on non-alcoholic fatty liver disease in high-fat diet rats via PPAR and AMPK signaling pathways. Journal of Functional Foods 2022;95:105195. [DOI: 10.1016/j.jff.2022.105195] [Reference Citation Analysis]
14 Peng Y, Gu T, Zhong T, Xiao Y, Sun Q. Endoplasmic Reticulum Stress in Metabolic Disorders: Opposite Roles of Phytochemicals and Food Contaminants. Current Opinion in Food Science 2022. [DOI: 10.1016/j.cofs.2022.100913] [Reference Citation Analysis]
15 Vachliotis ID, Vasiloglou MF, Kapama A, Matsagkos D, Goulas A, Papaioannidou P, Polyzos SA. Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life. Arab J Gastroenterol 2022:S1687-1979(22)00038-7. [PMID: 35927197 DOI: 10.1016/j.ajg.2022.05.006] [Reference Citation Analysis]
16 Wang X, Li W, Fu J, Ni Y, Liu K, Liu F. Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-8. [DOI: 10.1155/2022/6250751] [Reference Citation Analysis]
17 Liao Q, Wu T, Fu Q, Wang P, Zhao Y, Li Y, Xiao H, Zhou L, Song Z. Effects of Dietary Inclusion of β-Hydroxy-β-Methylbutyrate on Growth Performance, Fat Deposition, Bile Acid Metabolism, and Gut Microbiota Function in High-Fat and High-Cholesterol Diet-Challenged Layer Chickens. Curr Issues Mol Biol 2022;44:3413-27. [PMID: 36005131 DOI: 10.3390/cimb44080235] [Reference Citation Analysis]
18 Heath L, Aveyard P, Tomlinson JW, Cobbold JF, Koutoukidis DA. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. Hepatol Commun 2022. [PMID: 35903833 DOI: 10.1002/hep4.2044] [Reference Citation Analysis]
19 Nobakht M. Gh BF, Hasani Nourian Y, Arabfard M. Identification of Shared Gene Signatures in Different Stages of Nonalcoholic Fatty Liver Disease Using Integrated Microarray Datasets. Hepat Mon 2022;22. [DOI: 10.5812/hepatmon-122362] [Reference Citation Analysis]
20 Barana L, Colleluori G, Sulpizi MT, Ortenzi K, Farano L, Fanelli CG, Calafiore R, Dalla Ragione L, Pampanelli S. Efficacy of the holistic, psychonutritional approach of Centro DAI e Obesità di Città della Pieve in the management of type 2 diabetes among patients with obesity and dysfunctional eating. J Diabetes Metab Disord. [DOI: 10.1007/s40200-022-01085-1] [Reference Citation Analysis]
21 Zhou L, Shen H, Li X, Wang H. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease. Front Immunol 2022;13:951406. [DOI: 10.3389/fimmu.2022.951406] [Reference Citation Analysis]
22 Li Y, Duan Z. Updates in interaction of gastroesophageal reflux disease and extragastroesophageal digestive diseases. Expert Rev Gastroenterol Hepatol 2022;:1-11. [PMID: 35860994 DOI: 10.1080/17474124.2022.2056018] [Reference Citation Analysis]
23 Ristic-Medic D, Bajerska J, Vucic V. Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease. World J Gastroenterol 2022; 28(27): 3314-3333 [DOI: 10.3748/wjg.v28.i27.3314] [Reference Citation Analysis]
24 Cabré N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, Fernández-Arroyo S, Hernández-Aguilera A, Castañé H, Rodríguez-Tomàs E, París M, Sabench F, Castillo DD, Del Bas JM, Tomé M, Bodineau C, Sola-García A, López-Miranda J, Martín-Montalvo A, Durán RV, Vondriska TM, Rosa-Garrido M, Camps J, Menéndez JA, Joven J. Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis. Int J Mol Sci 2022;23:7830. [PMID: 35887177 DOI: 10.3390/ijms23147830] [Reference Citation Analysis]
25 Zeng Y, He H, An Z. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease. Dis Markers 2022;2022:1254014. [PMID: 35811662 DOI: 10.1155/2022/1254014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhang F, Zhang Z, Li Y, Sun Y, Zhou X, Chen X, Sun S. Integrated Bioinformatics Analysis Identifies Robust Biomarkers and Its Correlation With Immune Microenvironment in Nonalcoholic Fatty Liver Disease. Front Genet 2022;13:942153. [DOI: 10.3389/fgene.2022.942153] [Reference Citation Analysis]
27 Udoh US, Rajan PK, Nakafuku Y, Finley R, Sanabria JR. Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma. IJMS 2022;23:7734. [DOI: 10.3390/ijms23147734] [Reference Citation Analysis]
28 Vachher M, Bansal S, Kumar B, Yadav S, Arora T, Wali NM, Burman A. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. J Cell Biochem 2022. [PMID: 35818831 DOI: 10.1002/jcb.30252] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Cai Y, Chen X, Yi B, Li J, Wen Z. Pathophysiology roles for adenosine 2A receptor in obesity and related diseases. Obes Rev 2022;:e13490. [PMID: 35796566 DOI: 10.1111/obr.13490] [Reference Citation Analysis]
30 Sabench F, Bertran L, Vives M, París M, Aguilar C, Martínez S, Binetti J, Real M, Alibalic A, Richart C, del Castillo D, Auguet T. NASH Presence is Associated with a Lower Weight Loss One and 2 Years After Bariatric Surgery in Women with Severe Obesity. OBES SURG. [DOI: 10.1007/s11695-022-06175-w] [Reference Citation Analysis]
31 Huang C, Wei X, Luo Q, Xia Y, Pan T, He J, Jahangir A, Jia L, Liu W, Zou Y, Li L, Guo H, Geng Y, Chen Z. Loss of TRIM67 Attenuates the Progress of Obesity-Induced Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:7475. [PMID: 35806477 DOI: 10.3390/ijms23137475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
32 Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension 2022;79:1319-26. [PMID: 35465684 DOI: 10.1161/HYPERTENSIONAHA.122.17982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Sabir U, Irfan HM, Alamgeer, Umer I, Niazi ZR, Asjad HMM. Phytochemicals targeting NAFLD through modulating the dual function of forkhead box O1 (FOXO1) transcription factor signaling pathways. Naunyn Schmiedebergs Arch Pharmacol 2022;395:741-55. [PMID: 35357518 DOI: 10.1007/s00210-022-02234-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Perakakis N, Kokkinos A, Angelidi AM, Tsilingiris D, Gavrieli A, Yannakoulia M, Tentolouris N, Mantzoros CS. Changes in circulating levels of five proglucagon-derived peptides in response to intravenous or oral administration of glucose and lipids and in response to a mixed-meal in subjects with normal weight, overweight, and obesity. Clinical Nutrition 2022. [DOI: 10.1016/j.clnu.2022.07.001] [Reference Citation Analysis]
35 Zeng L, Zhong F, Chen Z, Li G, Zhu Q. Polygonatum sibiricum polysaccharides protect against obesity and non-alcoholic fatty liver disease in rats fed a high-fat diet. Food Science and Human Wellness 2022;11:1045-52. [DOI: 10.1016/j.fshw.2022.03.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 de Vasconcelos MHA, Tavares RL, Torres Junior EU, Dorand VAM, Batista KS, Toscano LT, Silva AS, de Magalhães Cordeiro AMT, de Albuquerque Meireles BRL, da Silva Araujo R, Alves AF, de Souza Aquino J. Extra virgin coconut oil (Cocos nucifera L.) exerts anti-obesity effect by modulating adiposity and improves hepatic lipid metabolism, leptin and insulin resistance in diet-induced obese rats. Journal of Functional Foods 2022;94:105122. [DOI: 10.1016/j.jff.2022.105122] [Reference Citation Analysis]
37 Ramanathan R, Ali AH, Ibdah JA. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. IJMS 2022;23:7280. [DOI: 10.3390/ijms23137280] [Reference Citation Analysis]
38 Ghaddar B, Gence L, Veeren B, Bringart M, Bascands J, Meilhac O, Diotel N. Aqueous Extract of Psiloxylon mauritianum, Rich in Gallic Acid, Prevents Obesity and Associated Deleterious Effects in Zebrafish. Antioxidants 2022;11:1309. [DOI: 10.3390/antiox11071309] [Reference Citation Analysis]
39 Luo S, He L, Zhang H, Li Z, Liu C, Chen T. Arabinoxylan from rice bran protects mice against high-fat diet-induced obesity and metabolic inflammation by modulating gut microbiota and short-chain fatty acids. Food Funct 2022. [PMID: 35758533 DOI: 10.1039/d2fo00569g] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Sánchez-bayona R, Bes-rastrollo M, Fernández-lázaro CI, Bastyr M, Madariaga A, Pons JJ, Martínez-gonzález MA, Toledo E. Vitamin D and Risk of Obesity-Related Cancers: Results from the SUN (‘Seguimiento Universidad de Navarra’) Project. Nutrients 2022;14:2561. [DOI: 10.3390/nu14132561] [Reference Citation Analysis]
41 Zhang S, Sun S, Wei X, Zhang M, Chen Y, Mao X, Chen G, Liu C. Short-term moderate caloric restriction in a high-fat diet alleviates obesity via AMPK/SIRT1 signaling in white adipocytes and liver. Food Nutr Res 2022;66. [PMID: 35721807 DOI: 10.29219/fnr.v66.7909] [Reference Citation Analysis]
42 Zang W, Zhu F, Yu Y, Li C. Computed Tomography Image Analysis of Body Fat Based on Multi-Image Information. BioMed Research International 2022;2022:1-11. [DOI: 10.1155/2022/8265211] [Reference Citation Analysis]
43 Li M, Xiao Y, Xiao L, Li Y, Jia M, Sun Y, Pan T, Zhou L, Li Y. Epigoitrin alleviates lipid and glucose metabolic disorders induced by a high-fat diet. Food Funct 2022. [PMID: 35723416 DOI: 10.1039/d2fo00242f] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Cen J, Han Y, Liu Y, Hu H. Evaluated Glomerular Filtration Rate Is Associated With Non-alcoholic Fatty Liver Disease: A 5-Year Longitudinal Cohort Study in Chinese Non-obese People. Front Nutr 2022;9:916704. [DOI: 10.3389/fnut.2022.916704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Boubertakh B, Silvestri C, Di Marzo V. Obesity: The Fat Tissue Disease Version of Cancer. Cells 2022;11:1872. [PMID: 35741001 DOI: 10.3390/cells11121872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Tao W, Cao W, Yu B, Chen H, Gong R, Luorong Q, Luo J, Yao L, Zhang D. Hawk tea prevents high-fat diet-induced obesity in mice by activating the AMPK/ACC/SREBP1c signaling pathways and regulating the gut microbiota. Food Funct 2022;13:6056-71. [PMID: 35437540 DOI: 10.1039/d1fo04260b] [Reference Citation Analysis]
47 Zhang Y, Huang J, Xia S, Yang Y, Dong K. Gender Difference in Liver Enzymes in Newly Defined Subgroups of Diabetes Revealed by a Data-Driven Cluster Analysis. Exp Clin Endocrinol Diabetes 2022. [PMID: 35640638 DOI: 10.1055/a-1799-8173] [Reference Citation Analysis]
48 Hassen G, Singh A, Belete G, Jain N, De la Hoz I, Camacho-leon GP, Dargie NK, Carrera KG, Alemu T, Jhaveri S, Solomon N. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus. [DOI: 10.7759/cureus.25495] [Reference Citation Analysis]
49 Yang Y, Li S, Xu Y, Ke J, Zhao D. The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes 2022;15:1505-15. [PMID: 35586202 DOI: 10.2147/DMSO.S350579] [Reference Citation Analysis]
50 Liu W, Shang J, Deng Y, Han X, Chen Y, Wang S, Yang R, Dong F, Shang H. Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo. J Ethnopharmacol 2022;:115382. [PMID: 35577161 DOI: 10.1016/j.jep.2022.115382] [Reference Citation Analysis]
51 Jarmakiewicz-czaja S, Sokal A, Pardak P, Filip R, Granito A. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/4344905] [Reference Citation Analysis]
52 Luo Y, Chen Q, Zou J, Fan J, Li Y, Luo Z. Chronic Intermittent Hypoxia Exposure Alternative to Exercise Alleviates High-Fat-Diet-Induced Obesity and Fatty Liver. Int J Mol Sci 2022;23:5209. [PMID: 35563600 DOI: 10.3390/ijms23095209] [Reference Citation Analysis]
53 Doycheva I, Ehrmann DA. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril 2022;117:897-911. [PMID: 35512974 DOI: 10.1016/j.fertnstert.2022.03.020] [Reference Citation Analysis]
54 Ye J, Tian X, Wang Q, Zheng J, Yang Y, Xu B, Zhang S, Yuan F, Yang Z. Monkfish Peptides Mitigate High Fat Diet-Induced Hepatic Steatosis in Mice. Marine Drugs 2022;20:312. [DOI: 10.3390/md20050312] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Wang D, He B. Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. Diabetes Metab Syndr Obes 2022;15:1281-91. [PMID: 35494531 DOI: 10.2147/DMSO.S362424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Curr Obes Rep 2022. [PMID: 35501557 DOI: 10.1007/s13679-022-00474-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Legaki AI, Moustakas II, Sikorska M, Papadopoulos G, Velliou RI, Chatzigeorgiou A. Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease. Curr Obes Rep 2022. [PMID: 35501558 DOI: 10.1007/s13679-022-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ji L, Li Q, He Y, Zhang X, Zhou Z, Gao Y, Fang M, Yu Z, Rodrigues RM, Gao Y, Li M. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: a promising drug Potentilla discolor Bunge. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.001] [Reference Citation Analysis]
59 Chen Z, Zhang Z, Liu J, Qi H, Li J, Chen J, Huang Q, Liu Q, Mi J, Li X. Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation. Front Cell Infect Microbiol 2022;12:853981. [DOI: 10.3389/fcimb.2022.853981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Lee H, Kim M. Metabolites of oregano (Origanum vulgare) seed and their anti-obesity effects on 3T3-L1 adipocytes through down-regulated adipogenesis. Food Sci Biotechnol. [DOI: 10.1007/s10068-022-01085-0] [Reference Citation Analysis]
61 Zeng B, Wu R, Chen Y, Chen W, Liu Y, Liao X, Guo G, Wang X. FTO knockout in adipose tissue effectively alleviates hepatic steatosis partially via increasing the secretion of adipocyte-derived IL-6. Gene 2022;818:146224. [PMID: 35085712 DOI: 10.1016/j.gene.2022.146224] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Yang Q, Zhang L, Li Q, Gu M, Qu Q, Yang X, Yi Q, Gu K, Kuang L, Hao M, Xu J, Yang H. Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. BMC Microbiol 2022;22. [DOI: 10.1186/s12866-022-02526-w] [Reference Citation Analysis]
63 Landgraf K, Kühnapfel A, Schlanstein M, Biemann R, Isermann B, Kempf E, Kirsten H, Scholz M, Körner A. Transcriptome Analyses of Adipose Tissue Samples Identify EGFL6 as a Candidate Gene Involved in Obesity-Related Adipose Tissue Dysfunction in Children. IJMS 2022;23:4349. [DOI: 10.3390/ijms23084349] [Reference Citation Analysis]
64 Manzano M, Giron MD, Salto R, Vilchez JD, Reche-perez FJ, Cabrera E, Linares-pérez A, Plaza-díaz J, Ruiz-ojeda FJ, Gil A, Rueda R, López-pedrosa JM. Quality More Than Quantity: The Use of Carbohydrates in High-Fat Diets to Tackle Obesity in Growing Rats. Front Nutr 2022;9:809865. [DOI: 10.3389/fnut.2022.809865] [Reference Citation Analysis]
65 Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. IJMS 2022;23:3668. [DOI: 10.3390/ijms23073668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
66 Kim HJ, Lee J, Chung MY, Park SH, Park JH, Choi HK, Hwang JT. Tamarixetin Abrogates Adipogenesis Through Inhibiting p300/CBP-Associated Factor Acetyltransferase Activity in 3T3-L1 Preadipocyte Cells. J Med Food 2022;25:272-80. [PMID: 35320012 DOI: 10.1089/jmf.2021.K.0126] [Reference Citation Analysis]
67 Yuan Z, Xiao-Wei L, Juan W, Xiu-Juan L, Nian-Yun Z, Lei S. HIIT and MICT attenuate high-fat diet-induced hepatic lipid accumulation and ER stress via the PERK-ATF4-CHOP signaling pathway. J Physiol Biochem 2022. [PMID: 35315506 DOI: 10.1007/s13105-022-00884-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci 2022;23:3107. [PMID: 35328527 DOI: 10.3390/ijms23063107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Chen X, Shi F, Xiao J, Huang F, Cheng F, Wang L, Ju Y, Zhou Y, Jia H. Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index. Front Endocrinol 2022;13:831960. [DOI: 10.3389/fendo.2022.831960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Muresanu C, Khalchitsky S. Updated Understanding of the Causes of Cancer, and a New Theoretical Perspective of Combinational Cancer Therapies, a Hypothesis. DNA Cell Biol 2022. [PMID: 35262416 DOI: 10.1089/dna.2021.1118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Giraudi PJ, Salvoza N, Bonazza D, Saitta C, Lombardo D, Casagranda B, de Manzini N, Pollicino T, Raimondo G, Tiribelli C, Palmisano S, Rosso N. Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2813. [PMID: 35269955 DOI: 10.3390/ijms23052813] [Reference Citation Analysis]
72 Sáenz de Urturi D, Buqué X, Porteiro B, Folgueira C, Mora A, Delgado TC, Prieto-Fernández E, Olaizola P, Gómez-Santos B, Apodaka-Biguri M, González-Romero F, Nieva-Zuluaga A, Ruiz de Gauna M, Goikoetxea-Usandizaga N, García-Rodríguez JL, Gutierrez de Juan V, Aurrekoetxea I, Montalvo-Romeral V, Novoa EM, Martín-Guerrero I, Varela-Rey M, Bhanot S, Lee R, Banales JM, Syn WK, Sabio G, Martínez-Chantar ML, Nogueiras R, Aspichueta P. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis. Nat Commun 2022;13:1096. [PMID: 35232994 DOI: 10.1038/s41467-022-28749-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
73 Vachliotis I, Goulas A, Papaioannidou P, Polyzos SA. Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones (Athens) 2022;21:41-9. [PMID: 34854066 DOI: 10.1007/s42000-021-00339-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
74 Zhang LY, Shi HH, Wang CC, Wang YM, Wei ZH, Xue CH, Mao XZ, Zhang TT. Targeted Lipidomics Reveal the Effects of Different Phospholipids on the Phospholipid Profiles of Hepatic Mitochondria and Endoplasmic Reticulum in High-Fat/High-Fructose-Diet-Induced Nonalcoholic Fatty Liver Disease Mice. J Agric Food Chem 2022. [PMID: 35212227 DOI: 10.1021/acs.jafc.1c07538] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Luo Q, Wei R, Cai Y, Zhao Q, Liu Y, Liu WJ. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Front Med 2022;9:793203. [DOI: 10.3389/fmed.2022.793203] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Zhang Y, Liu X, Zhang H, Wang X. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol 2022;13:836455. [DOI: 10.3389/fendo.2022.836455] [Reference Citation Analysis]
77 Cai X, Gao J, Hu J, Wen W, Zhu Q, Wang M, Liu S, Hong J, Wu T, Yang S, Tuerxun G, Li N, Awan FM. Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study. Disease Markers 2022;2022:1-10. [DOI: 10.1155/2022/4930355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
78 Weinstein G, O'Donnell A, Davis-Plourde K, Zelber-Sagi S, Ghosh S, DeCarli CS, Thibault EG, Sperling RA, Johnson KA, Beiser AS, Seshadri S. Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study. J Alzheimers Dis 2022. [PMID: 35213373 DOI: 10.3233/JAD-215409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
79 Uematsu S, Ohno S, Tanaka KY, Hatano A, Kokaji T, Ito Y, Kubota H, Hironaka KI, Suzuki Y, Matsumoto M, Nakayama KI, Hirayama A, Soga T, Kuroda S. Multi-omics-based label-free metabolic flux inference reveals obesity-associated dysregulatory mechanisms in liver glucose metabolism. iScience 2022;25:103787. [PMID: 35243212 DOI: 10.1016/j.isci.2022.103787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
80 Zhou M, Li F, Tang H, Wu S, Meng L, Dong Y, Wang F, Quach B, Yang Y, Ma J, Baker JS. The hypertriglyceridemic waist phenotype is associated with fatty liver and glycometabolic profiles in overweight and obese adults: a cross-sectional study. Sci Rep 2022;12. [DOI: 10.1038/s41598-021-00825-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Aghakhani L, Haghighat N, Amini M, Hosseini SV, Masoumi SJ, Mansour-ghanaei F. The Risk Factors of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery in Iran. Gastroenterology Research and Practice 2022;2022:1-6. [DOI: 10.1155/2022/5980390] [Reference Citation Analysis]
82 Mohammad Rahimi GR, Attarzadeh Hosseini SR. Effect of Aerobic Exercise Alone or in Conjunction With Diet on Liver Function, Insulin Resistance and Lipids in Non-Alcoholic Fatty Liver Disease. Biol Res Nurs 2022;:10998004211068026. [PMID: 35130757 DOI: 10.1177/10998004211068026] [Reference Citation Analysis]
83 Sabir U, Irfan HM, Alamgeer, Ullah A, Althobaiti YS, Asim MH. Reduction of Hepatic Steatosis, Oxidative Stress, Inflammation, Ballooning and Insulin Resistance After Therapy with Safranal in NAFLD Animal Model: A New Approach. JIR 2022;Volume 15:1293-316. [DOI: 10.2147/jir.s354878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 Marinovic M, Sousa-filho C, Batista F, Avelino T, Cogliati B, Figueira A, Otton R, Rodrigues A. Green tea extract increases adiponectin and PPARα levels to improve hepatic steatosis. The Journal of Nutritional Biochemistry 2022. [DOI: 10.1016/j.jnutbio.2022.108957] [Reference Citation Analysis]
85 Metzner V, Herzog G, Heckel T, Bischler T, Hasinger J, Otto C, Fassnacht M, Geier A, Seyfried F, Dischinger U. Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. JCM 2022;11:753. [DOI: 10.3390/jcm11030753] [Reference Citation Analysis]
86 Wu J, Miyasaka K, Yamada W, Takeda S, Shimizu N, Shimoda H. The Anti-Adiposity Mechanisms of Ampelopsin and Vine Tea Extract in High Fat Diet and Alcohol-Induced Fatty Liver Mouse Models. Molecules 2022;27:607. [PMID: 35163881 DOI: 10.3390/molecules27030607] [Reference Citation Analysis]
87 Chen J, Lei S, Huang Y, Zha X, Gu L, Zhou D, Li J, Liu F, Li N, Du L, Huang X, Lin Z, Bu L, Qu S. The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery. Lipids Health Dis 2022;21:10. [PMID: 35034646 DOI: 10.1186/s12944-022-01622-0] [Reference Citation Analysis]
88 Zou J, Xiong H, Zhang H, Hu C, Lu S, Zou Y. Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02099-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity 2022;55:31-55. [PMID: 35021057 DOI: 10.1016/j.immuni.2021.12.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 44.0] [Reference Citation Analysis]
90 Han HS, Chung KS, Shin YK, Yu JS, Kang SH, Lee SH, Lee KT. Effect of Standardized Hydrangea serrata (Thunb.) Ser. Leaves Extract on Body Weight and Body Fat Reduction in Overweight or Obese Humans: A Randomized Double-Blind Placebo-Controlled Study. Nutrients 2022;14:208. [PMID: 35011083 DOI: 10.3390/nu14010208] [Reference Citation Analysis]
91 Kong S, Huang X, Cao H, Bai Y, Che Q, Nie H, Su Z. Anti-obesity effects of galacto-oligosaccharides in obese rats. Eur J Pharmacol 2021;:174728. [PMID: 34965390 DOI: 10.1016/j.ejphar.2021.174728] [Reference Citation Analysis]
92 Regueiras A, Huguet Á, Conde T, Couto D, Domingues P, Domingues MR, Costa AM, Silva JLD, Vasconcelos V, Urbatzka R. Potential Anti-Obesity, Anti-Steatosis, and Anti-Inflammatory Properties of Extracts from the Microalgae Chlorella vulgaris and Chlorococcum amblystomatis under Different Growth Conditions. Mar Drugs 2021;20:9. [PMID: 35049863 DOI: 10.3390/md20010009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Wang J, Su Z, Feng Y, Xi R, Liu J, Wang P. Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China. BMC Gastroenterol 2021;21:482. [PMID: 34923965 DOI: 10.1186/s12876-021-02072-1] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
94 Zheng W, Song Z, Li S, Hu M, Shaukat H, Qin H. Protective Effects of Sesamol against Liver Oxidative Stress and Inflammation in High-Fat Diet-Induced Hepatic Steatosis. Nutrients 2021;13:4484. [PMID: 34960036 DOI: 10.3390/nu13124484] [Reference Citation Analysis]
95 Juárez-Fernández M, Porras D, Petrov P, Román-Sagüillo S, García-Mediavilla MV, Soluyanova P, Martínez-Flórez S, González-Gallego J, Nistal E, Jover R, Sánchez-Campos S. The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. Antioxidants (Basel) 2021;10:2001. [PMID: 34943104 DOI: 10.3390/antiox10122001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
96 Tan CT, Soh NJH, Chang HC, Yu VC. p62/SQSTM1 in liver diseases: the usual suspect with multifarious identities. FEBS J 2021. [PMID: 34882306 DOI: 10.1111/febs.16317] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
97 Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open 2021;12:100149. [PMID: 34870138 DOI: 10.1016/j.metop.2021.100149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
98 Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol 2021;21:453. [PMID: 34861841 DOI: 10.1186/s12876-021-02038-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
99 Laurindo CP, Rego Gregorio KC, Rippi Moreno AC, Viudes Agostinho JM, Campos EC, Nai GA, Nunes MT, Seraphim PM. Resistance training mitigates hepato-cardiac changes and muscle mitochondrial protein reductions in rats with diet-induced obesity. Heliyon 2021;7:e08374. [PMID: 34841103 DOI: 10.1016/j.heliyon.2021.e08374] [Reference Citation Analysis]
100 Ghanemi A, Yoshioka M, St-Amand J. Ageing and Obesity Shared Patterns: From Molecular Pathogenesis to Epigenetics. Diseases 2021;9:87. [PMID: 34940025 DOI: 10.3390/diseases9040087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
101 Yan JX, Pan BJ, Zhao PP, Wang LT, Liu JF, Fu SB. Serum ferritin is correlated with non-alcoholic fatty liver disease in middle-aged and older patients with type 2 diabetes. Endocr Connect 2021;10:1560-9. [PMID: 34738917 DOI: 10.1530/EC-21-0367] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Gong L, Wang Z, Wang Z, Zhang Z. Sestrin2 as a Potential Target for Regulating Metabolic-Related Diseases. Front Endocrinol (Lausanne) 2021;12:751020. [PMID: 34803916 DOI: 10.3389/fendo.2021.751020] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
103 Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis 2021:jjab212. [PMID: 34972203 DOI: 10.1093/ecco-jcc/jjab212] [Reference Citation Analysis]
104 Patel S, Kumthekar A. Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. Rheumatol Ther 2021. [PMID: 34797530 DOI: 10.1007/s40744-021-00397-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Bima A, Eldakhakhny B, Nuwaylati D, Alnami A, Ajabnoor M, Elsamanoudy A. The Interplay of Vitamin D Deficiency and Cellular Senescence in The Pathogenesis of Obesity-Related Co-Morbidities. Nutrients 2021;13:4127. [PMID: 34836382 DOI: 10.3390/nu13114127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Johnson AL, Hayward KL, Patel P, Horsfall LU, Cheah AEZ, Irvine KM, Russell AW, Stuart KA, Williams S, Hartel G, Valery PC, Powell EE. Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests. Hepatol Commun 2021. [PMID: 34783191 DOI: 10.1002/hep4.1852] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
107 Wang G, Wu S, Wu C, Zhang Q, Wu F, Yu B, Zhang S, Wu C, Wu G, Zhong Y. Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. J Cell Mol Med 2021. [PMID: 34761514 DOI: 10.1111/jcmm.17042] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
108 Chaney A. Obesity and Nonalcoholic Fatty Liver Disease. Nurs Clin North Am 2021;56:543-52. [PMID: 34749893 DOI: 10.1016/j.cnur.2021.07.009] [Reference Citation Analysis]
109 Barge S, Deka B, Kashyap B, Bharadwaj S, Kandimalla R, Ghosh A, Dutta PP, Samanta SK, Manna P, Borah JC, Talukdar NC. Astragalin mediates the pharmacological effects of Lysimachia candida Lindl on adipogenesis via downregulating PPARG and FKBP51 signaling cascade. Phytother Res 2021. [PMID: 34734439 DOI: 10.1002/ptr.7320] [Reference Citation Analysis]
110 Li J, Allen AM, Shah VH, Manduca A, Ehman RL, Yin M. Longitudinal Changes in MR Elastography-based Biomarkers in Obese Patients Treated with Bariatric Surgery. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01146-0. [PMID: 34757198 DOI: 10.1016/j.cgh.2021.10.033] [Reference Citation Analysis]
111 Huang T, Yu L, Pan H, Ma Z, Wu T, Zhang L, Liu K, Qi Q, Miao W, Song Z, Zhang H, Zhou L, Li Y. Integrated Transcriptomic and Translatomic Inquiry of the Role of Betaine on Lipid Metabolic Dysregulation Induced by a High-Fat Diet. Front Nutr 2021;8:751436. [PMID: 34708066 DOI: 10.3389/fnut.2021.751436] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 Albracht-Schulte K, Wilson S, Johnson P, Pahlavani M, Ramalingam L, Goonapienuwala B, Kalupahana NS, Festuccia WT, Scoggin S, Kahathuduwa CN, Moustaid-Moussa N. Sex-Dependent Effects of Eicosapentaenoic Acid on Hepatic Steatosis in UCP1 Knockout Mice. Biomedicines 2021;9:1549. [PMID: 34829779 DOI: 10.3390/biomedicines9111549] [Reference Citation Analysis]
113 Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocr Rev 2021:bnab034. [PMID: 34698815 DOI: 10.1210/endrev/bnab034] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
114 Wu L, Zhang M, Hu H, Wan Q. Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: a secondary retrospective study. Lipids Health Dis 2021;20:142. [PMID: 34689770 DOI: 10.1186/s12944-021-01577-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
115 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Reference Citation Analysis]
116 Ryyti R, Pemmari A, Peltola R, Hämäläinen M, Moilanen E. Effects of Lingonberry (Vaccinium vitis-idaea L.) Supplementation on Hepatic Gene Expression in High-Fat Diet Fed Mice. Nutrients 2021;13:3693. [PMID: 34835949 DOI: 10.3390/nu13113693] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:11128. [PMID: 34681787 DOI: 10.3390/ijms222011128] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
118 Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes Obes Metab 2021. [PMID: 34622555 DOI: 10.1111/dom.14569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
119 Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021;161:1657-69. [PMID: 34602251 DOI: 10.1053/j.gastro.2021.07.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 28] [Article Influence: 1.0] [Reference Citation Analysis]
120 King H, Soh JE, Thompson WW, Brown JR, Rapposelli K, Vellozzi C. Testing for Hepatitis C Virus Infection Among Adults Aged ≥18 in the United States, 2013-2017. Public Health Rep 2021;:333549211047236. [PMID: 34606398 DOI: 10.1177/00333549211047236] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Neto J, Jantsch J, de Oliveira S, Braga MF, Castro LFDS, Diniz BF, Moreira JCF, Giovenardi M, Porawski M, Guedes RP. DHA/EPA supplementation decreases anxiety-like behaviour, but it does not ameliorate metabolic profile in obese male rats. Br J Nutr 2021;:1-11. [PMID: 34605386 DOI: 10.1017/S0007114521003998] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Osorio-Conles Ó, Vega-Beyhart A, Ibarzabal A, Balibrea JM, Graupera I, Rimola J, Vidal J, de Hollanda A. A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity. Int J Mol Sci 2021;22:10541. [PMID: 34638880 DOI: 10.3390/ijms221910541] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
123 Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
124 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
125 Le TNH, Choi HJ, Jun HS. Ethanol Extract of Liriope platyphylla Root Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice via Regulation of Lipogenesis and Lipid Uptake. Nutrients 2021;13:3338. [PMID: 34684339 DOI: 10.3390/nu13103338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Schwenger KJP, Kiu A, AlAli M, Alhanaee A, Fischer SE, Allard JP. Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis. Nutrition 2021;93:111491. [PMID: 34739937 DOI: 10.1016/j.nut.2021.111491] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Aguiar AJFC, de Queiroz JLC, Santos PPA, Camillo CS, Serquiz AC, Costa IS, Oliveira GS, Gomes AFT, Matias LLR, Costa ROA, Passos TS, Morais AHA. Beneficial Effects of Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles on Hepatic Injury Induced High Glycemic Index Diet: A Preclinical Study. Int J Mol Sci 2021;22:9968. [PMID: 34576130 DOI: 10.3390/ijms22189968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Mo M, Huang Z, Liang Y, Liao Y, Xia N. The safety and efficacy evaluation of Sodium-Glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty Liver disease: An updated meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00733-7. [PMID: 34507895 DOI: 10.1016/j.dld.2021.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
129 van den Hoek AM, de Jong JCBC, Worms N, van Nieuwkoop A, Voskuilen M, Menke AL, Lek S, Caspers MPM, Verschuren L, Kleemann R. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. Metabolism 2021;124:154873. [PMID: 34478753 DOI: 10.1016/j.metabol.2021.154873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
130 Liu Z, Wang J, Chen S, Xu C, Zhang Y. Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study. Environ Health 2021;20:98. [PMID: 34461916 DOI: 10.1186/s12940-021-00783-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
131 Dilimulati D, Cai M, Lin Z, Zhang Y, Du L, Zhou D, Zhu J, Su L, Wang Y, Zhang M, Qu S. Correlation Between Sex Hormones and Non-alcoholic Fatty Liver Disease Before and After Laparoscopic Sleeve Gastrectomy. Obes Surg 2021;31:4901-10. [PMID: 34453689 DOI: 10.1007/s11695-021-05663-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
132 Dietert RR. Microbiome First Medicine in Health and Safety. Biomedicines 2021;9:1099. [PMID: 34572284 DOI: 10.3390/biomedicines9091099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Zuccaro A, Zapatería B, Sánchez-Alonso MG, Haro M, Limones M, Terrados G, Izquierdo A, Corrales P, Medina-Gómez G, Herradón G, Sevillano J, Ramos-Álvarez MDP. Pleiotrophin Deficiency Induces Browning of Periovarian Adipose Tissue and Protects against High-Fat Diet-Induced Hepatic Steatosis. Int J Mol Sci 2021;22:9261. [PMID: 34502170 DOI: 10.3390/ijms22179261] [Reference Citation Analysis]
134 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
135 Saha MR, Dey P. Pharmacological benefits of Acacia against metabolic diseases: intestinal-level bioactivities and favorable modulation of gut microbiota. Arch Physiol Biochem 2021;:1-17. [PMID: 34411504 DOI: 10.1080/13813455.2021.1966475] [Reference Citation Analysis]
136 Park E, Park EY. Inverse Association between Serum 25-hydroxyvitamin D Levels and Risk of Suspected Non-Alcoholic Fatty Liver Disease in Obese Population. Int J Environ Res Public Health 2021;18:8682. [PMID: 34444431 DOI: 10.3390/ijerph18168682] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
137 Karimi-Sales E, Mohaddes G, Alipour MR. Hepatoprotection of capsaicin in alcoholic and non-alcoholic fatty liver diseases. Arch Physiol Biochem 2021;:1-11. [PMID: 34396890 DOI: 10.1080/13813455.2021.1962913] [Reference Citation Analysis]
138 Liu H, Chen Y, Wen Y, Zhu S, Huang S, He L, Hou S, Lai X, Chen S, Dai Z, Liang J. Phloridzin Ameliorates Lipid Deposition in High-Fat-Diet-Fed Mice with Nonalcoholic Fatty Liver Disease via Inhibiting the mTORC1/SREBP-1c Pathway. J Agric Food Chem 2021;69:8671-83. [PMID: 34342231 DOI: 10.1021/acs.jafc.1c01645] [Reference Citation Analysis]
139 Santos-Sánchez G, Cruz-Chamorro I, Álvarez-Ríos AI, Fernández-Santos JM, Vázquez-Román MV, Rodríguez-Ortiz B, Álvarez-Sánchez N, Álvarez-López AI, Millán-Linares MDC, Millán F, Pedroche J, Fernández-Pachón MS, Lardone PJ, Guerrero JM, Bejarano I, Carrillo-Vico A. Lupinus angustifolius Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE-/- Mice. Antioxidants (Basel) 2021;10:1222. [PMID: 34439470 DOI: 10.3390/antiox10081222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
140 Yang T, Zhao B, Pei D. Estimation of the Prevalence of Nonalcoholic Fatty Liver Disease in an Adult Population in Northern China Using the Data Mining Approach. Diabetes Metab Syndr Obes 2021;14:3437-45. [PMID: 34349537 DOI: 10.2147/DMSO.S320808] [Reference Citation Analysis]
141 Heo JH, Lee SR, Jo SL, Ko JW, Kwon HJ, Hong EJ. Hepatic LKB1 Reduces the Progression of Non-Alcoholic Fatty Liver Disease via Genomic Androgen Receptor Signaling. Int J Mol Sci 2021;22:7904. [PMID: 34360667 DOI: 10.3390/ijms22157904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Murakami E, Nakahara T, Hiramatsu A, Morio K, Fujino H, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Aikata H, Fudeyasu K, Nakashima Y, Iwaki D, Jodai D, Ohigashi T, Nishimura Y, Minamoto Y, Nagao A, Yoneda M, Saeki Y, Tanabe K, Ohdan H, Chayama K. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients. Medicine (Baltimore) 2021;100:e26436. [PMID: 34190166 DOI: 10.1097/MD.0000000000026436] [Reference Citation Analysis]
143 Peng K, Wang S, Gao L, You H. A nomogram incorporated lifestyle indicators for predicting nonalcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e26415. [PMID: 34190160 DOI: 10.1097/MD.0000000000026415] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Matsumoto Y, Fujita S, Yamagishi A, Shirai T, Maeda Y, Suzuki T, Kobayashi KI, Inoue J, Yamamoto Y. Brown Rice Inhibits Development of Nonalcoholic Fatty Liver Disease in Obese Zucker (fa/fa) Rats by Increasing Lipid Oxidation Via Activation of Retinoic Acid Synthesis. J Nutr 2021:nxab188. [PMID: 34224565 DOI: 10.1093/jn/nxab188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Ji L, Cai X, Bai Y, Li T. Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. Int J Gen Med 2021;14:2909-22. [PMID: 34234521 DOI: 10.2147/IJGM.S319759] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
146 Maciejewska-Markiewicz D, Stachowska E, Hawryłkowicz V, Stachowska L, Prowans P. The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD). Biomolecules 2021;11:937. [PMID: 34202667 DOI: 10.3390/biom11070937] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
147 Makri ES, Goulas A, Polyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 2021;907:174272. [PMID: 34147478 DOI: 10.1016/j.ejphar.2021.174272] [Reference Citation Analysis]
148 Perakakis N, Chrysafi P, Feigh M, Veidal SS, Mantzoros CS. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. Int J Mol Sci 2021;22:6332. [PMID: 34199317 DOI: 10.3390/ijms22126332] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
149 Ather JL, Van Der Vliet KE, Mank MM, Reed LF, Dixon AE, Poynter ME. Obese adipose tissue modulates proinflammatory responses of mouse airway epithelial cells. Am J Physiol Regul Integr Comp Physiol 2021;321:R79-90. [PMID: 34105399 DOI: 10.1152/ajpregu.00316.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Barakat B, Almeida MEF. Biochemical and immunological changes in obesity. Arch Biochem Biophys 2021;708:108951. [PMID: 34102165 DOI: 10.1016/j.abb.2021.108951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Longo L, de Souza VEG, Stein DJ, de Freitas JS, Uribe-Cruz C, Torres ILS, Álvares-da-Silva MR. Transcranial direct current stimulation (tDCS) has beneficial effects on liver lipid accumulation and hepatic inflammatory parameters in obese rats. Sci Rep 2021;11:11037. [PMID: 34040131 DOI: 10.1038/s41598-021-90563-2] [Reference Citation Analysis]
152 Ghaddar B, Bringart M, Lefebvre d'Hellencourt C, Meilhac O, Diotel N. Deleterious Effects of Overfeeding on Brain Homeostasis and Plasticity in Adult Zebrafish. Zebrafish 2021;18:190-206. [PMID: 34028307 DOI: 10.1089/zeb.2020.1962] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
153 Sheng G, Peng N, Hu C, Zhong L, Zhong M, Zou Y. The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population. Lipids Health Dis 2021;20:50. [PMID: 33993872 DOI: 10.1186/s12944-021-01479-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
154 Qi R, Han X, Wang J, Qiu X, Wang Q, Yang F. MicroRNA-489-3p promotes adipogenesis by targeting the Postn gene in 3T3-L1 preadipocytes. Life Sci 2021;278:119620. [PMID: 34004251 DOI: 10.1016/j.lfs.2021.119620] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
155 Hasan EM, Abd Al Aziz RA, Sabry D, Badary HA, Gaber Y, Yosry A, Zakaria Z. The association of adiponectin gene polymorphisms with susceptibility and progression of NAFLD in a cohort of Egyptian patients. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00103-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Liu F, Ye Q, Liang J, Cao YY, Shi LL, Zhao X, Xiang HL. Nutritional status and energy metabolism in elderly patients with nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(9): 467-473 [DOI: 10.11569/wcjd.v29.i9.467] [Reference Citation Analysis]
157 Cabré N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, Fernández-Arroyo S, Hernández-Aguilera A, Castañé H, Rodríguez-Tomàs E, París M, Sabench F, Del Castillo D, Del Bas JM, Tomé M, Bodineau C, Sola-García A, López-Miranda J, Martín-Montalvo A, Durán RV, Vondriska TM, Rosa-Garrido M, Camps J, Menéndez JA, Joven J. Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression. J Hepatol 2021:S0168-8278(21)00302-0. [PMID: 33961941 DOI: 10.1016/j.jhep.2021.04.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Brown SA, Izzy M, Watt KD. Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology 2021;73:2051-62. [PMID: 33047343 DOI: 10.1002/hep.31595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
160 Ceylan H. Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis. Med Oncol 2021;38:63. [PMID: 33900477 DOI: 10.1007/s12032-021-01510-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
161 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
162 Boutari C, Polyzos SA, Mantzoros CS. Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism 2021;122:154781. [PMID: 33901501 DOI: 10.1016/j.metabol.2021.154781] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
163 Kiran S, Kumar V, Kumar S, Price RL, Singh UP. Adipocyte, Immune Cells, and miRNA Crosstalk: A Novel Regulator of Metabolic Dysfunction and Obesity. Cells 2021;10:1004. [PMID: 33923175 DOI: 10.3390/cells10051004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
164 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 160] [Article Influence: 12.0] [Reference Citation Analysis]
165 Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. Liver Int 2021;41:1853-66. [PMID: 33788377 DOI: 10.1111/liv.14888] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
166 Liu C, Shao M, Lu L, Zhao C, Qiu L, Liu Z. Obesity, insulin resistance and their interaction on liver enzymes. PLoS One 2021;16:e0249299. [PMID: 33882064 DOI: 10.1371/journal.pone.0249299] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Negi CK, Khan S, Dirven H, Bajard L, Bláha L. Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:4282. [PMID: 33924165 DOI: 10.3390/ijms22084282] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
168 Polyzos SA, Papaefthymiou A, Doulberis M, Mavridoglou G, Kountouras J. Helicobacter pylori infection and diabetes mellitus. Diabetes Metab Syndr 2021;15:845-6. [PMID: 33873053 DOI: 10.1016/j.dsx.2021.03.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Risi R, Tozzi R, Watanabe M. Beyond weight loss in nonalcoholic fatty liver disease: the role of carbohydrate restriction. Curr Opin Clin Nutr Metab Care 2021;24:349-53. [PMID: 33871418 DOI: 10.1097/MCO.0000000000000762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne) 2021;8:615978. [PMID: 33937277 DOI: 10.3389/fmed.2021.615978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
171 Notarnicola M, Osella AR, Caruso MG, Pesole PL, Lippolis A, Tutino V, Bonfiglio C, De Nunzio V, Scavo MP, Mirizzi A, Franco I, Lippolis T, D'Alessandro R, Refolo MG, Messa C. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. Int J Mol Sci 2021;22:3899. [PMID: 33918878 DOI: 10.3390/ijms22083899] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
172 Khalafi M, Symonds ME. The impact of high intensity interval training on liver fat content in overweight or obese adults: A meta-analysis. Physiol Behav 2021;236:113416. [PMID: 33823178 DOI: 10.1016/j.physbeh.2021.113416] [Reference Citation Analysis]
173 Shin Y, Lee M, Lee D, Jang J, Shin SS, Yoon M. Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice. Int J Mol Sci 2021;22:3675. [PMID: 33916086 DOI: 10.3390/ijms22073675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
174 Moucharite MA, Zhang J, Giffin R. Factors and Economic Outcomes Associated with Documented Difficult Intubation in the United States. Clinicoecon Outcomes Res 2021;13:227-39. [PMID: 33833535 DOI: 10.2147/CEOR.S304037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
175 Wang Q, Shi X, Wang J, Zhang J, Xu C. Low serum vitamin D concentrations are associated with obese but not lean NAFLD: a cross-sectional study. Nutr J 2021;20:30. [PMID: 33794916 DOI: 10.1186/s12937-021-00690-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
176 Mooli RGR, Rodriguez J, Takahashi S, Solanki S, Gonzalez FJ, Ramakrishnan SK, Shah YM. Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver. Cell Mol Gastroenterol Hepatol 2021;12:585-97. [PMID: 33798787 DOI: 10.1016/j.jcmgh.2021.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
177 Zou Y, Zhong L, Hu C, Zhong M, Peng N, Sheng G. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. Lipids Health Dis 2021;20:28. [PMID: 33766067 DOI: 10.1186/s12944-021-01457-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
178 Subramanian G, Shanmugamprema D, Subramani R, Muthuswamy K, Ponnusamy V, Tankay K, Velusamy T, Krishnan V, Subramaniam S. Anti-Obesity Effect of T. Chebula Fruit Extract on High Fat Diet Induced Obese Mice: A Possible Alternative Therapy. Mol Nutr Food Res 2021;65:e2001224. [PMID: 33754444 DOI: 10.1002/mnfr.202001224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
179 Flessa CM, Kyrou I, Nasiri-Ansari N, Kaltsas G, Papavassiliou AG, Kassi E, Randeva HS. Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives. Curr Obes Rep 2021;10:134-61. [PMID: 33751456 DOI: 10.1007/s13679-021-00431-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
180 Izzo C, Annunziata M, Melara G, Sciorio R, Dallio M, Masarone M, Federico A, Persico M. The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. Nutrients 2021;13:933. [PMID: 33805795 DOI: 10.3390/nu13030933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
181 Miao Y, Qin H, Zhong Y, Huang K, Rao C. Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue. J Endocrinol 2021;249:83-93. [PMID: 33705351 DOI: 10.1530/JOE-20-0503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
182 Barbois S, Stürm N, Aron-Wisnewsky J, Clément K, Bedossa P, Genser L, Hilleret MN, Costentin C, Reche F, Arvieux C, Borel AL. Decision Tree for the Performance of Intraoperative Liver Biopsy During Bariatric Surgery. Obes Surg 2021;31:2641-8. [PMID: 33665755 DOI: 10.1007/s11695-021-05309-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease. Hepatol Int 2021;15:350-65. [PMID: 33656663 DOI: 10.1007/s12072-021-10138-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
184 Han HS, Lee HH, Gil HS, Chung KS, Kim JK, Kim DH, Yoon J, Chung EK, Lee JK, Yang WM, Shin YK, Ahn HS, Lee SH, Lee KT. Standardized hot water extract from the leaves of Hydrangea serrata (Thunb.) Ser. alleviates obesity via the AMPK pathway and modulation of the gut microbiota composition in high fat diet-induced obese mice. Food Funct 2021;12:2672-85. [PMID: 33656018 DOI: 10.1039/d0fo02185g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
185 Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction? J Clin Med 2021;10:924. [PMID: 33804296 DOI: 10.3390/jcm10050924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
186 Rivera K, Quiñones V, Amigo L, Santander N, Salas-Pérez F, Xavier A, Fernández-Galilea M, Carrasco G, Cabrera D, Arrese M, Busso D, Andia ME, Rigotti A. Lipoprotein receptor SR-B1 deficiency enhances adipose tissue inflammation and reduces susceptibility to hepatic steatosis during diet-induced obesity in mice. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158909. [PMID: 33631309 DOI: 10.1016/j.bbalip.2021.158909] [Reference Citation Analysis]
187 Cho S, Lee H, Han J, Lee H, Kattia RO, Nelson ZV, Choi S, Kim SY, Park HY, Jeong HG, Jeong TS. Viburnum stellato-tomentosum Extract Suppresses Obesity and Hyperglycemia through Regulation of Lipid Metabolism in High-Fat Diet-Fed Mice. Molecules 2021;26:1052. [PMID: 33671428 DOI: 10.3390/molecules26041052] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
188 Tashiro Y, Han Q, Tan Y, Sugisawa N, Yamamoto J, Nishino H, Inubushi S, Sun YU, Lim H, Aoki T, Murakami M, Takahashi Y, Bouvet M, Hoffman RM. Oral Recombinant Methioninase Prevents Nonalcoholic Fatty Liver Disease in Mice on a High Fat Diet. In Vivo 2020;34:979-84. [PMID: 32354883 DOI: 10.21873/invivo.11866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Liang W, Zhou K, Jian P, Chang Z, Zhang Q, Liu Y, Xiao S, Zhang L. Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis. Front Pharmacol 2021;12:622841. [PMID: 33679403 DOI: 10.3389/fphar.2021.622841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
190 Maltais M, Brisson D, Gaudet D. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. J Clin Med 2021;10:669. [PMID: 33572376 DOI: 10.3390/jcm10040669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
191 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
192 Hernández-Aguilera A, Casacuberta N, Castañé H, Fibla M, Fernández-Arroyo S, Fort-Gallifa I, París M, Sabench F, Del Castillo D, Baiges-Gaya G, Rodríguez-Tomàs E, Sans T, Camps J, Joven J. Nonalcoholic Steatohepatitis Modifies Serum Iron-Related Variables in Patients with Morbid Obesity. Biol Trace Elem Res 2021. [PMID: 33559024 DOI: 10.1007/s12011-021-02610-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
193 Shao J, Liang Y, Li Y, Ding R, Zhu M, You W, Wang Z, Huang B, Wu M, Zhang T, Li K, Wu W, Wu L, Wang Q, Xia X, Wang S, Lu L. Implications of liver injury in risk-stratification and management of patients with COVID-19. Hepatol Int. 2021;15:202-212. [PMID: 33548030 DOI: 10.1007/s12072-020-10123-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
194 Li Y, Lin Y, Han X, Li W, Yan W, Ma Y, Lu X, Huang X, Bai R, Zhang H. GSK3 inhibitor ameliorates steatosis through the modulation of mitochondrial dysfunction in hepatocytes of obese patients. iScience 2021;24:102149. [PMID: 33665568 DOI: 10.1016/j.isci.2021.102149] [Reference Citation Analysis]
195 Kenđel Jovanović G, Mrakovcic-Sutic I, Pavičić Žeželj S, Benjak Horvat I, Šuša L, Rahelić D, Klobučar Majanović S. Metabolic and Hepatic Effects of Energy-Reduced Anti-Inflammatory Diet in Younger Adults with Obesity. Can J Gastroenterol Hepatol 2021;2021:6649142. [PMID: 33628758 DOI: 10.1155/2021/6649142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
196 An M, Park YH, Lim YH. Antiobesity and antidiabetic effects of the dairy bacterium Propionibacterium freudenreichii MJ2 in high-fat diet-induced obese mice by modulating lipid metabolism. Sci Rep 2021;11:2481. [PMID: 33510408 DOI: 10.1038/s41598-021-82282-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
197 Zhang Y, Li B, Liu N, Wang P, He J. Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals. Int J Endocrinol 2021;2021:6678755. [PMID: 33574841 DOI: 10.1155/2021/6678755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
198 Mansoor S, Jain P, Hassan N, Farooq U, Mirza MA, Pandith AA, Iqbal Z. Role of Genetic and Dietary Implications in the Pathogenesis of Global Obesity. Food Reviews International. [DOI: 10.1080/87559129.2021.1874409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
199 Michałowska J, Miller-Kasprzak E, Bogdański P. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients 2021;13:351. [PMID: 33503878 DOI: 10.3390/nu13020351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
200 Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97 [PMID: 33520110 DOI: 10.4239/wjd.v12.i1.84] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
201 AlFaris NA, Alshammari GM, AlTamimi JZ, AlMousa LA, AlKehayez NM, Aljabryn DH, Alagal RI, Yahya MA. The protective effect of shrimp cooked in different methods on high-cholesterol- induced fatty liver in rats. Saudi J Biol Sci 2021;28:170-82. [PMID: 33424294 DOI: 10.1016/j.sjbs.2020.09.036] [Reference Citation Analysis]
202 Zhou X, Yuan Y, Teng F, Li K, Luo S, Zhang P, Liu D, Zhang H, Zhang J. Obesity-induced upregulation of microRNA-183-5p promotes hepatic triglyceride accumulation by targeting the B-cell translocation gene 1. Life Sci 2021;268:119011. [PMID: 33421522 DOI: 10.1016/j.lfs.2020.119011] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
203 Juárez-Fernández M, Porras D, García-Mediavilla MV, Román-Sagüillo S, González-Gallego J, Nistal E, Sánchez-Campos S. Aging, Gut Microbiota and Metabolic Diseases: Management through Physical Exercise and Nutritional Interventions. Nutrients 2020;13:E16. [PMID: 33374578 DOI: 10.3390/nu13010016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
204 Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:592373. [PMID: 33424768 DOI: 10.3389/fendo.2020.592373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
205 Luo Y, Lin H. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immun Inflamm Dis 2021;9:59-73. [PMID: 33332766 DOI: 10.1002/iid3.391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
206 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
207 Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134:8-19. [PMID: 33323806 DOI: 10.1097/cm9.0000000000001263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
208 Zembroski AS, Buhman KK, Aryal UK. Proteome and phosphoproteome characterization of liver in the postprandial state from diet-induced obese and lean mice. J Proteomics 2021;232:104072. [PMID: 33309929 DOI: 10.1016/j.jprot.2020.104072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
209 Harvey I, Boudreau A, Stephens JM. Adipose tissue in health and disease. Open Biol 2020;10:200291. [PMID: 33292104 DOI: 10.1098/rsob.200291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
210 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
211 Sugama J, Moritoh Y, Yashiro H, Tsuchimori K, Watanabe M. Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice. Pharmacol Res 2021;163:105337. [PMID: 33276106 DOI: 10.1016/j.phrs.2020.105337] [Reference Citation Analysis]
212 Koutoukidis DA, Koshiaris C, Henry JA, Noreik M, Morris E, Manoharan I, Tudor K, Bodenham E, Dunnigan A, Jebb SA, Aveyard P. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2021;115:154455. [PMID: 33259835 DOI: 10.1016/j.metabol.2020.154455] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
213 Li J, Hu Q, Xiao-Yu D, Zhu L, Miao YF, Kang HX, Zhao XL, Yao JQ, Long D, Tang WF, Wan MH. Effect of Sheng-Jiang Powder on Gut Microbiota in High-Fat Diet-Induced NAFLD. Evid Based Complement Alternat Med 2020;2020:6697638. [PMID: 33293992 DOI: 10.1155/2020/6697638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
214 Piché ME, Tardif I, Auclair A, Poirier P. Effects of bariatric surgery on lipid-lipoprotein profile. Metabolism 2021;115:154441. [PMID: 33248063 DOI: 10.1016/j.metabol.2020.154441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
215 Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis 2020;19:245. [PMID: 33239040 DOI: 10.1186/s12944-020-01419-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
216 López-Taboada I, González-Pardo H, Conejo NM. Western Diet: Implications for Brain Function and Behavior. Front Psychol 2020;11:564413. [PMID: 33329193 DOI: 10.3389/fpsyg.2020.564413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
217 Pfohl M, DaSilva NA, Marques E, Agudelo J, Liu C, Goedken M, Slitt AL, Seeram NP, Ma H. Hepatoprotective and anti-inflammatory effects of a standardized pomegranate (Punica granatum) fruit extract in high fat diet-induced obese C57BL/6 mice. Int J Food Sci Nutr 2021;72:499-510. [PMID: 33203257 DOI: 10.1080/09637486.2020.1849041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Bae JY. Resistance Exercise Regulates Hepatic Lipolytic Factors as Effective as Aerobic Exercise in Obese Mice. Int J Environ Res Public Health 2020;17:E8307. [PMID: 33182720 DOI: 10.3390/ijerph17228307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Kouvari M, Boutari C, Chrysohoou C, Fragkopoulou E, Antonopoulou S, Tousoulis D, Pitsavos C, Panagiotakos DB, Mantzoros CS; ATTICA study Investigators. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study. Clin Nutr 2021;40:3314-24. [PMID: 33234342 DOI: 10.1016/j.clnu.2020.10.058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
220 Cai X, Aierken X, Ahmat A, Cao Y, Zhu Q, Wu T, Li N. A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. Biomed Res Int 2020;2020:8852198. [PMID: 33204721 DOI: 10.1155/2020/8852198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
221 Omokaro SO, Golden JK. The regulatory state of nonalcoholic steatohepatitis and metabolism. Endocrinol Diabetes Metab 2020;3:e00113. [PMID: 33102795 DOI: 10.1002/edm2.113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Bonfim THFD, Tavares RL, de Vasconcelos MHA, Gouveia M, Nunes PC, Soares NL, Alves RC, de Carvalho JLP, Alves AF, Pereira RA, Cardoso GA, Silva AS, Aquino JS. Potentially obesogenic diets alter metabolic and neurobehavioural parameters in Wistar rats: a comparison between two dietary models. J Affect Disord 2021;279:451-61. [PMID: 33120246 DOI: 10.1016/j.jad.2020.10.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
223 Kim MN, Lo CH, Corey KE, Liu PH, Ma W, Zhang X, Jovani M, Song M, Chan AT, Simon TG. Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women. Metabolism 2020;113:154398. [PMID: 33058854 DOI: 10.1016/j.metabol.2020.154398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
224 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 13.5] [Reference Citation Analysis]
225 Makri E, Kita M, Goulas A, Papaioannidou P, Efstathiadou ZA, Adamidou F, Polyzos SA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr 2020;14:1913-9. [PMID: 33011499 DOI: 10.1016/j.dsx.2020.09.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
226 Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 29.0] [Reference Citation Analysis]
227 Puthenpura MM, Patel V, Fam J, Katz L, Tichansky DS, Myers S. The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature. Obes Surg 2020;30:5108-16. [PMID: 32981002 DOI: 10.1007/s11695-020-05002-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
228 Ramos LF, Silva CM, Pansa CC, Moraes KCM. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. Expert Rev Gastroenterol Hepatol 2021;15:25-40. [PMID: 32892668 DOI: 10.1080/17474124.2020.1820321] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
229 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
230 Chen PH, Tsai SY, Pan CH, Chang HM, Chen YL, Su SS, Chen CC, Kuo CJ. Age Effect on Incidence, Physical, and Psychiatric Comorbidity for Sudden Cardiac Death in Schizophrenia: Effet de l'âge sur l'incidence, la comorbidité physique et psychiatrique de la mort cardiaque subite dans la schizophrénie. Can J Psychiatry 2021;66:367-75. [PMID: 32799653 DOI: 10.1177/0706743720948429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
231 Masaki S, Hashimoto Y, Kunisho S, Kimoto A, Kitadai Y. Fatty change of the liver microenvironment influences the metastatic potential of colorectal cancer. Int J Exp Pathol 2020;101:162-70. [PMID: 32783302 DOI: 10.1111/iep.12371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
232 Polyzos SA, Mousiolis A, Mintziori G, Goulis DG. Nonalcoholic fatty liver disease in males with low testosterone concentrations. Diabetes Metab Syndr 2020;14:1571-7. [PMID: 32947757 DOI: 10.1016/j.dsx.2020.07.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
233 Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open 2020;10:e036663. [PMID: 32747349 DOI: 10.1136/bmjopen-2019-036663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
234 Alvarez CS, Graubard BI, Thistle JE, Petrick JL, McGlynn KA. Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up. Hepatology 2020;72:430-40. [PMID: 31733165 DOI: 10.1002/hep.31040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
235 Tung Y, Liang Z, Chou S, Ho C, Kuo Y, Cheng K, Lu T, Chang Y, Pan M. Fermented Soy Paste Alleviates Lipid Accumulation in the Liver by Regulating the AMPK Pathway and Modulating Gut Microbiota in High-Fat-Diet-Fed Rats. J Agric Food Chem 2020;68:9345-57. [DOI: 10.1021/acs.jafc.0c02919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
236 Machado AS, Oliveira JR, Lelis DF, de Paula AMB, Guimarães ALS, Andrade JMO, Brandi IV, Santos SHS. Oral Probiotic Bifidobacterium Longum Supplementation Improves Metabolic Parameters and Alters the Expression of the Renin-Angiotensin System in Obese Mice Liver. Biol Res Nurs 2021;23:100-8. [PMID: 32700545 DOI: 10.1177/1099800420942942] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
237 Pomeroy J, Krentz AD, Richardson JG, Berg RL, VanWormer JJ, Haws RM. Bardet-Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome. Pediatr Obes 2021;16:e12703. [PMID: 32700463 DOI: 10.1111/ijpo.12703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
238 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
239 Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.Diabetol Metab Syndr. 2020;12:60. [PMID: 32684985 DOI: 10.1186/s13098-020-00570-y] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 56.0] [Reference Citation Analysis]
240 Song B, Sun Y, Chu Y, Wang J, Zheng H, Liu L, Cai W, Zhang H. Ginsenoside Rb1 Alleviated High-Fat-Diet-Induced Hepatocytic Apoptosis via Peroxisome Proliferator-Activated Receptor γ. Biomed Res Int 2020;2020:2315230. [PMID: 32733933 DOI: 10.1155/2020/2315230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
241 Sakasai-Sakai A, Takata T, Takeuchi M. Intracellular Toxic Advanced Glycation End-Products Promote the Production of Reactive Oxygen Species in HepG2 Cells. Int J Mol Sci 2020;21:E4861. [PMID: 32660150 DOI: 10.3390/ijms21144861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
242 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020; 26(25): 3528-3541 [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
243 Doulberis M, Papadimitriou K, Papaefthymiou A, Kountouras J, Polyzos SA. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine 2020;1:170-83. [DOI: 10.37349/emed.2020.00012] [Reference Citation Analysis]
244 Dougherty JA, Guirguis E, Thornby KA. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Ann Pharmacother 2021;55:65-79. [PMID: 32571083 DOI: 10.1177/1060028020935105] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
245 Siddiqui MT, Amin H, Garg R, Chadalavada P, Al-Yaman W, Lopez R, Singh A. Medications in type-2 diabetics and their association with liver fibrosis. World J Gastroenterol 2020; 26(23): 3249-3259 [PMID: 32684739 DOI: 10.3748/wjg.v26.i23.3249] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis 2020;19:145. [PMID: 32563249 DOI: 10.1186/s12944-020-01326-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
247 Lee I, Kim J, Kang H. Estimated Cardiorespiratory Fitness Attenuates the Impacts of Sarcopenia and Obesity on Non-Alcoholic Fatty Liver in Korean Adults. Int J Environ Res Public Health 2020;17:E3902. [PMID: 32486399 DOI: 10.3390/ijerph17113902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
248 Adami GF, Carbone F, Montecucco F, Camerini G, Cordera R. Adipose Tissue Composition in Obesity and After Bariatric Surgery. Obes Surg 2019;29:3030-8. [PMID: 31190263 DOI: 10.1007/s11695-019-04030-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
249 Park E, Lee CG, Jeong H, Yeo S, Kim JA, Jeong SY. Antiadipogenic Effects of Mixtures of Cornus officinalis and Ribes fasciculatum Extracts on 3T3-L1 Preadipocytes and High-Fat Diet-Induced Mice. Molecules 2020;25:E2350. [PMID: 32443487 DOI: 10.3390/molecules25102350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
250 Emamat H, Ghalandari H, Tangestani H, Abdollahi A, Hekmatdoost A. Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. EXCLI J 2020;19:620-6. [PMID: 32483408 DOI: 10.17179/excli2020-1226] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
251 Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. Diabetes Metab J 2019;43:127-43. [PMID: 30993937 DOI: 10.4093/dmj.2019.0034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
252 Gerardi G, Cavia-saiz M, Rivero-pérez MD, González-sanjosé ML, Muñiz P. Wine pomace product modulates oxidative stress and microbiota in obesity high-fat diet-fed rats. Journal of Functional Foods 2020;68:103903. [DOI: 10.1016/j.jff.2020.103903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
253 Ji Y, Yin Y, Sun L, Zhang W. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:E3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
254 Zeng J, Yang RX, Sun C, Pan Q, Zhang RN, Chen GY, Hu Y, Fan JG. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol 2020; 26(15): 1792-1804 [PMID: 32351294 DOI: 10.3748/wjg.v26.i15.1792] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
255 Ma N, Ma R, Tang K, Li X, He B. Roux-en-Y Gastric Bypass in Obese Diabetic Rats Promotes Autophagy to Improve Lipid Metabolism through mTOR/p70S6K Signaling Pathway. J Diabetes Res 2020;2020:4326549. [PMID: 32309446 DOI: 10.1155/2020/4326549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
256 Koutoukidis DA, Jebb SA, Aveyard P, Astbury NM. The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial. Obes Facts 2020;13:144-51. [PMID: 32200381 DOI: 10.1159/000505667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
257 Zhao Y, Wu TY, Zhao MF, Li CJ. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease. J Biol Chem 2020;295:5152-62. [PMID: 32139507 DOI: 10.1074/jbc.REV119.008897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
258 Pompili S, Vetuschi A, Gaudio E, Tessitore A, Capelli R, Alesse E, Latella G, Sferra R, Onori P. Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH. Nutrition 2020;75-76:110782. [PMID: 32268264 DOI: 10.1016/j.nut.2020.110782] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
259 Polyzos SA, Kountouras J, Mantzoros CS. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism 2020;104:154144. [DOI: 10.1016/j.metabol.2020.154144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
260 Lee M, Kim H, Lee J, Lee S, Cho J, Lee D, Lee N, Lee H, Moon S, Son C. Synergistic hepatoprotective effects of CGplus on CCl4-induced acute injury. Journal of Ethnopharmacology 2020;249:112441. [DOI: 10.1016/j.jep.2019.112441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
261 Yang Q, Sun S, Liu W, Liu Q, Wang J. Hypoxia training improves hepatic steatosis partly by downregulation of CB1 receptor in obese mice. Biochem Biophys Res Commun. 2020;525:639-645. [PMID: 32122652 DOI: 10.1016/j.bbrc.2020.02.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
262 Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1525. [PMID: 32102237 DOI: 10.3390/ijms21041525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
263 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 65.5] [Reference Citation Analysis]
264 Liu R, Wang M, Li E, Yang Y, Li J, Chen S, Shen WJ, Azhar S, Guo Z, Hu Z. Dysregulation of microRNA-125a contributes to obesity-associated insulin resistance and dysregulates lipid metabolism in mice. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158640. [PMID: 31988048 DOI: 10.1016/j.bbalip.2020.158640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
265 Singh A, Amin H, Garg R, Gupta M, Lopez R, Alkhouri N, Mccullough A. Increased Prevalence of Obesity and Metabolic Syndrome in Patients with Alcoholic Fatty Liver Disease. Dig Dis Sci 2020;65:3341-9. [DOI: 10.1007/s10620-020-06056-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
266 Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, Pan B, Guo W, Li X, Gao X. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26:444-453. [PMID: 31968197 DOI: 10.4158/ep-2019-0342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
267 Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8:76-86. [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
268 Zemel MB. Natural Products: New Hope for Nonalcoholic Steatohepatitis? J Med Food 2019;22:1187-8. [PMID: 31834843 DOI: 10.1089/jmf.2019.29004.mbz] [Reference Citation Analysis]
269 Ando Y, Yamazaki M, Yamada H, Munetsuna E, Fujii R, Mizuno G, Ichino N, Osakabe K, Sugimoto K, Ishikawa H, Ohashi K, Teradaira R, Ohta Y, Hamajima N, Hashimoto S, Suzuki K. Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. Sci Rep 2019;9:18856. [PMID: 31827150 DOI: 10.1038/s41598-019-55076-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
270 Katsiki N, Gastaldelli A, Mikhailidis DP. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy? Metabolism 2019;101:154010. [DOI: 10.1016/j.metabol.2019.154010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
271 Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism 2020;103:154028. [PMID: 31785257 DOI: 10.1016/j.metabol.2019.154028] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
272 Rospleszcz S, Lorbeer R, Storz C, Schlett CL, Meisinger C, Thorand B, Rathmann W, Bamberg F, Lieb W, Peters A. Association of longitudinal risk profile trajectory clusters with adipose tissue depots measured by magnetic resonance imaging. Sci Rep 2019;9:16972. [PMID: 31740739 DOI: 10.1038/s41598-019-53546-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
273 Boutari C, Bouzoni E, Joshi A, Stefanakis K, Farr OM, Mantzoros CS. Metabolism updates: new directions, techniques, and exciting research that is broadening the horizons. Metabolism 2020;102:154009. [PMID: 31715175 DOI: 10.1016/j.metabol.2019.154009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
274 Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 2019;101:154005. [PMID: 31711876 DOI: 10.1016/j.metabol.2019.154005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 18.0] [Reference Citation Analysis]
275 Montesano A, Senesi P, Vacante F, Mollica G, Benedini S, Mariotti M, Luzi L, Terruzzi I. L-Carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers. J Endocrinol Invest 2020;43:493-503. [PMID: 31705397 DOI: 10.1007/s40618-019-01134-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
276 Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, Georgopoulos NA, Vryonidou A. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 2020;67:1-8. [PMID: 31538291 DOI: 10.1007/s12020-019-02085-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
277 Li S, He N, Wang L. Efficiently Anti-Obesity Effects of Unsaturated Alginate Oligosaccharides (UAOS) in High-Fat Diet (HFD)-Fed Mice. Mar Drugs 2019;17:E540. [PMID: 31533255 DOI: 10.3390/md17090540] [Cited by in Crossref: 14] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
278 Venetsanaki V, Karabouta Z, Polyzos SA. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. Eur J Pharmacol. 2019;863:172661. [PMID: 31536725 DOI: 10.1016/j.ejphar.2019.172661] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
279 Polyzos SA, Kountouras J, Goulas A, Duntas L. Selenium and selenoprotein P in nonalcoholic fatty liver disease. Hormones (Athens) 2020;19:61-72. [PMID: 31493247 DOI: 10.1007/s42000-019-00127-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
280 Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA, Noreik M, Jebb SA, Aveyard P. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019;. [PMID: 31260026 DOI: 10.1001/jamainternmed.2019.2248] [Cited by in Crossref: 69] [Cited by in F6Publishing: 89] [Article Influence: 23.0] [Reference Citation Analysis]
281 Tommasi S, Besaratinia A. DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E2791. [PMID: 31387232 DOI: 10.3390/ijerph16152791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
282 Salva-Pastor N, Chávez-Tapia NC, Uribe M, Nuño-Lámbarri N. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol 2019;194:105445. [PMID: 31381969 DOI: 10.1016/j.jsbmb.2019.105445] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
283 Petrucciani N, Gugenheim J. Molecular pathways between obesity, non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Hepatobiliary Surg Nutr 2019;8:395-7. [PMID: 31489312 DOI: 10.21037/hbsn.2019.03.13] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
284 Sowers JR, Habibi J, Aroor AR, Yang Y, Lastra G, Hill MA, Whaley-Connell A, Jaisser F, Jia G. Epithelial sodium channels in endothelial cells mediate diet-induced endothelium stiffness and impaired vascular relaxation in obese female mice. Metabolism 2019;99:57-66. [PMID: 31302199 DOI: 10.1016/j.metabol.2019.153946] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
285 Katsiki N, Perakakis N, Mantzoros C. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus? Metabolism 2019;98:iii-ix. [PMID: 31301336 DOI: 10.1016/j.metabol.2019.07.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
286 Polyzos SA, Kountouras J, Mantzoros CS. Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction? Metabolism 2019;96:iii-v. [DOI: 10.1016/j.metabol.2019.05.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
287 Farr OM, Pilitsi E, Mantzoros CS. Of mice and men: incretin actions in the central nervous system. Metabolism 2019;98:121-35. [PMID: 31173757 DOI: 10.1016/j.metabol.2019.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
288 Polyzos SA, Mantzoros CS. Obesity: seize the day, fight the fat. Metabolism 2019;92:1-5. [DOI: 10.1016/j.metabol.2018.12.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
289 Anastasilakis AD, Sternthal E, Mantzoros CS. Beyond glycemic control: New guidance on cardio-renal protection. Metabolism 2019;99:113-5. [PMID: 30797784 DOI: 10.1016/j.metabol.2019.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
290 Mehrdoost S, Yaghmaei P, Jafary H, Ebrahim-Habibi A. The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. Iran J Basic Med Sci 2021;24:451-9. [PMID: 34094026 DOI: 10.22038/ijbms.2021.52239.11822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]